Heterociclos con nitrógeno (N)

Applications 1-(2,2-Dihydroxyethyl)-6-(methoxycarbonyl)-4-oxo-1,4-dihydropyridine-3-carboxylic Acid is an intermediate in the synthesis of Bictegravir-15N, d2 (B382096), which is the labeled version of Bictegravir, which is a novel, potent inhibitor of HIV-1 integrase with an IC50 of 7.5 nM. References Tsiang M. et al.: Antimicrob Agents Chemother. 2016 Nov 21;60(12):7086-7097;

Please enquire for more information about 6-Chloro-N,N'-bis(2,4-dimethylphenyl)-1,3,5-triazine-2,4-diamine including the price, delivery time and more detailed product information at the technical inquiry form on this page

Please enquire for more information about 5,5-Dimethyl-3-(4-phenylpiperazinyl)cyclohex-2-en-1-one including the price, delivery time and more detailed product information at the technical inquiry form on this page

(9H-Fluoren-9-yl)methyl2,4-dichloro-7,8-dihydropyrido[4,3-d]pyrimidine-6(5H)-carboxylate is a prodrug that is metabolized to the active form of the drug, 9-[(fluorenylmethoxy)carbonyl]-2,4-dichloro-7,8-dihydropyrido[4,3-d]pyrimidine. This compound binds to receptors in the pancreas and gastrointestinal tract and reduces gastric acid secretion. It also has significant binding to receptors in the nervous system. The drug may be used for treatment of pancreatic disorders such as diabetes mellitus. It may also be used for treatment of gastrointestinal disorders such as peptic ulcers or gastritis. The drug has been shown to reduce symptoms associated with nervous system disorders such as Parkinson's disease or

2,6-Dichloropyridine-4-carboxaldehyde is a synthetic compound that is an aldehyde. It can be used to synthesize 7-deazapurine through dehydration. The oxidation products of 2,6-Dichloropyridine-4-carboxaldehyde are isonicotinic acid and the corresponding alcohol. The reaction time for this compound is kinetic and it has been shown to have homologous reactivity with purines. Electrospray ionization was used to analyze the reactivity of this compound and other related compounds in order to determine its active site.

BQ-610 is a novel peptide that has been shown to reduce the severity of mucosal inflammation in animal models of inflammatory bowel disease. It functions by binding to myofibroblasts, which are cells that produce an extracellular matrix and collagen. BQ-610 also blocks signalling pathways that are responsible for the production of TNF-α, MMP-2, and other molecules involved in the pathogenesis of inflammatory bowel disease. BQ-610 is effective at reducing inflammation in animal models of colitis, but not in human colonic epithelial cells or human colonic tissue.

Please enquire for more information about 4-Methyl-4-(5-methyl-1,3,4-oxadiazol-2-yl)piperidine dihydrochloride including the price, delivery time and more detailed product information at the technical inquiry form on this page

Please enquire for more information about 4-(2-Pyridin-2-ylethoxy)aniline dihydrochloride including the price, delivery time and more detailed product information at the technical inquiry form on this page

Please enquire for more information about tert-Butyl4-(1H-indazol-3-yl)piperazine-1-carboxylate including the price, delivery time and more detailed product information at the technical inquiry form on this page

Please enquire for more information about tert-Butyl (2-(hydroxymethyl)pyridin-3-yl)carbamate including the price, delivery time and more detailed product information at the technical inquiry form on this page

Applications 4-Bromo-7H-pyrrolo[2,3-d]pyrimidine

Please enquire for more information about 6-Chloro-N,N'-bis(4-ethoxyphenyl)-1,3,5-triazine-2,4-diamine including the price, delivery time and more detailed product information at the technical inquiry form on this page